These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 7553880

  • 21. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease.
    Harris DT, LoCascio J, Besencon FJ.
    Bone Marrow Transplant; 1994 Oct; 14(4):545-53. PubMed ID: 7858529
    [Abstract] [Full Text] [Related]

  • 22. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
    Long GS, Cramer DV, Harnaha JB, Hiserodt JC.
    Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
    [Abstract] [Full Text] [Related]

  • 23. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR, Parreira A, Ascensão JL.
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [Abstract] [Full Text] [Related]

  • 24. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
    Klingemann HG, Wong E, Maki G.
    Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
    [Abstract] [Full Text] [Related]

  • 25. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 26. Cell therapy: achievements and perspectives.
    Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A, Rondelli D, Zanon P, Tura S.
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [Abstract] [Full Text] [Related]

  • 27. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG, Deal H, Reid D, Eaves CJ.
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [Abstract] [Full Text] [Related]

  • 28. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells.
    Midis GP, Gupta VK, Fabian DF, Lefor AT.
    J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171
    [Abstract] [Full Text] [Related]

  • 29. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
    He Y, Wang HH, Wang M, Zhou Z, Zhai WJ, Huang Y, Jiang EL, Wang ZD, Zhou SY, Liu QG, Feng SZ, Han MZ.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
    [Abstract] [Full Text] [Related]

  • 30. Natural killer cells in peripheral blood after autologous bone marrow transplantation: a combined phenotypic and functional study.
    Jorgensen H, Hokland P, Jensen T, Basse P, Hokland M.
    Nat Immun; 1995 Feb; 14(3):164-72. PubMed ID: 8832900
    [Abstract] [Full Text] [Related]

  • 31. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
    Condiotti R, Nagler A.
    Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
    [Abstract] [Full Text] [Related]

  • 32. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [Abstract] [Full Text] [Related]

  • 33. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
    Komatsu F, Kajiwara M.
    Oncol Res; 1998 Aug; 10(10):483-9. PubMed ID: 10338151
    [Abstract] [Full Text] [Related]

  • 34. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 35. A novel telomerase-based approach to detect natural cell-mediated cytotoxic activity against tumor cells in vitro.
    Faraoni I, Cottarelli A, Giuliani A, Bonmassar L, Rossi L, Bonmassar E.
    J Immunol Methods; 2005 Oct 30; 305(2):162-72. PubMed ID: 16165149
    [Abstract] [Full Text] [Related]

  • 36. Effect of interleukin-15 and Flt3-ligand on natural killer cell expansion and activation: umbilical cord vs. adult peripheral blood mononuclear cells.
    Lin SJ, Yang MH, Chao HC, Kuo ML, Huang JL.
    Pediatr Allergy Immunol; 2000 Aug 30; 11(3):168-74. PubMed ID: 10981526
    [Abstract] [Full Text] [Related]

  • 37. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
    Mazumder A.
    Cancer J Sci Am; 1997 Dec 30; 3 Suppl 1():S37-42. PubMed ID: 9457392
    [Abstract] [Full Text] [Related]

  • 38. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
    Zheng YJ, Zhang J, Wang SM, Zhang JR.
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr 30; 24(4):392-6. PubMed ID: 15090306
    [Abstract] [Full Text] [Related]

  • 39. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
    Uberti J, Martilotti F, Chou TH, Kaplan J.
    Blood; 1992 Jan 01; 79(1):261-8. PubMed ID: 1370206
    [Abstract] [Full Text] [Related]

  • 40. Effects of X-ray irradiation on natural killer (NK) cell system. II. Increased sensitivity to natural killer cytotoxic factor (NKCF).
    Uchida A, Mizutani Y, Nagamuta M, Ikenaga M.
    Immunopharmacol Immunotoxicol; 1989 Jan 01; 11(2-3):521-34. PubMed ID: 2621326
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.